These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 30345466)
1. Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. Roviello G; Petrioli R; Bonetta A; Conca R; Rodriquenz MG; Aieta M Invest New Drugs; 2018 Dec; 36(6):1110-1115. PubMed ID: 30345466 [TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611 [TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030 [TBL] [Abstract][Full Text] [Related]
4. Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone. Yang Z; Ni Y; Zhao D; Zhang Y; Wang J; Jiang L; Chen D; Wu Z; Wang Y; He L; Shi Y; Zhou F; Zeng H; Li Y BMC Cancer; 2021 Aug; 21(1):919. PubMed ID: 34388965 [TBL] [Abstract][Full Text] [Related]
5. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882 [TBL] [Abstract][Full Text] [Related]
6. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780 [TBL] [Abstract][Full Text] [Related]
7. Corticosteroid switch after progression on abiraterone acetate plus prednisone. Roviello G; Sobhani N; Corona SP; D'Angelo A Int J Clin Oncol; 2020 Feb; 25(2):240-246. PubMed ID: 31705219 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967 [TBL] [Abstract][Full Text] [Related]
9. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821 [TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374 [TBL] [Abstract][Full Text] [Related]
11. The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. Ryan CJ; Crawford ED; Shore ND; Underwood W; Taplin ME; Londhe A; Francis PSJ; Phillips J; McGowan T; Kantoff PW J Urol; 2018 Aug; 200(2):344-352. PubMed ID: 29630978 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Posadas EM; Chi KN; de Wit R; de Jonge MJA; Attard G; Friedlander TW; Yu MK; Hellemans P; Chien C; Abrams C; Jiao JJ; Saad F Clin Cancer Res; 2020 Jul; 26(14):3517-3524. PubMed ID: 32366670 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676 [TBL] [Abstract][Full Text] [Related]
14. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer. Scott LJ Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727 [TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621 [TBL] [Abstract][Full Text] [Related]
16. Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. Fang WY; Wang PF; Fan YC; Shih HJ Urol Int; 2021; 105(5-6):380-385. PubMed ID: 32791510 [TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study. Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291 [TBL] [Abstract][Full Text] [Related]
18. Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer. Ni YC; Zhao JG; Zhang MN; Zhang YJ; Yang ZY; Chen N; Chen JR; Shen PF; Sun GX; Zhang XM; Li YH; Zeng H Asian J Androl; 2022; 24(2):154-160. PubMed ID: 34380864 [TBL] [Abstract][Full Text] [Related]
19. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099 [TBL] [Abstract][Full Text] [Related]
20. Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review. Xiong X; Qiu S; Yi X; Xu H; Liao D; Lei H; Bai S; Peng G; Ai J; Yang L Urol Oncol; 2021 Nov; 39(11):754-763. PubMed ID: 34330654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]